Cannabis and Depression

There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of depression. The association between cannabis use and depression may be stronger among men during adolescence and emerging adulthood and stronger in women during midlife. There is an indication for potential genetic correlation contributing to the comorbidity of cannabis dependence and major depression, namely that serotonin (5-HT) may mediate such association and there is also evidence for specific risk alleles for cannabis addiction. There is preclinical evidence that alteration in the endocannabinoid system could potentially benefit patients suffering from depression. However, the issue of using cannabis as an anti-depressant is at an early stage of examination and there is little evidence to support it. Finally, there has been little support to the notion that selective serotonin reuptake inhibitors (SSRIs) may be effective in decreasing depressive symptoms or rates of substance use in adolescents treated for depression and a co-occurring substance use disorder. In conclusion, despite methodological limitations, research in the past decades has broadened our knowledge on the association between cannabis use and depression from epidemiological, neurological, genetic, and pharmacological perspectives.

Keywords: Anxiety Disorders; Bipolar Disorder; Cannabis; Major Depressive Disorder; Mental illness; Mood disorders.

Similar articles

Gilder DA, Ehlers CL. Gilder DA, et al. Am J Addict. 2012 Nov-Dec;21(6):536-43. doi: 10.1111/j.1521-0391.2012.00281.x. Epub 2012 Sep 27. Am J Addict. 2012. PMID: 23082832 Free PMC article.

Sanches RF, Marques JM. Sanches RF, et al. Braz J Psychiatry. 2010 Jun;32(2):173-80. doi: 10.1590/s1516-44462010000200014. Braz J Psychiatry. 2010. PMID: 20658056 Review. Portuguese.

Onaemo VN, Fawehinmi TO, D'Arcy C. Onaemo VN, et al. J Affect Disord. 2021 Feb 15;281:467-475. doi: 10.1016/j.jad.2020.12.043. Epub 2020 Dec 16. J Affect Disord. 2021. PMID: 33360749 Review.

Durdle H, Lundahl LH, Johanson CE, Tancer M. Durdle H, et al. Depress Anxiety. 2008;25(3):241-7. doi: 10.1002/da.20297. Depress Anxiety. 2008. PMID: 17345601

Chabrol H, Duconge E, Roura C, Casas C. Chabrol H, et al. Encephale. 2004 Mar-Apr;30(2):141-6. doi: 10.1016/s0013-7006(04)95424-3. Encephale. 2004. PMID: 15107716 French.

Cited by

Baddenhausen S, Lutz B, Hofmann C. Baddenhausen S, et al. Front Mol Neurosci. 2024 Apr 4;17:1379889. doi: 10.3389/fnmol.2024.1379889. eCollection 2024. Front Mol Neurosci. 2024. PMID: 38660383 Free PMC article.

Myran DT, Harrison LD, Pugliese M, Tanuseputro P, Gaudreault A, Fiedorowicz JG, Solmi M. Myran DT, et al. EClinicalMedicine. 2024 Feb 5;69:102455. doi: 10.1016/j.eclinm.2024.102455. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38544799 Free PMC article.

Scott C, Hall S, Zhou J, Lehmann C. Scott C, et al. J Clin Med. 2023 Dec 30;13(1):227. doi: 10.3390/jcm13010227. J Clin Med. 2023. PMID: 38202234 Free PMC article. Review.

Etami Y, Lildharrie C, Manza P, Wang GJ, Volkow ND. Etami Y, et al. Genes (Basel). 2023 Nov 23;14(12):2113. doi: 10.3390/genes14122113. Genes (Basel). 2023. PMID: 38136935 Free PMC article. Review.

Licciardi M, Utzeri E, Marchetti MF, Nissardi V, Cecchetto G, Montisci M, Montisci R. Licciardi M, et al. BMC Cardiovasc Disord. 2023 Oct 25;23(1):518. doi: 10.1186/s12872-023-03566-4. BMC Cardiovasc Disord. 2023. PMID: 37875800 Free PMC article. Review.

References

    1. Ablon SL, Goodwin FK (1974) High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry 131(4):448–453 - PubMed - DOI
    1. Agrawal A, Lynskey MT (2006) The genetic epidemiology of cannabis use, abuse and dependence. [research support, N.I.H., extramural review]. Addiction 101(6):801–812. https://doi.org/10.1111/j.1360-0443.2006.01399.x - DOI - PubMed
    1. Agrawal A, Wetherill L, Dick DM, Xuei X, Hinrichs A, Hesselbrock V, Kramer J, Nurnberger JI, Schuckit M, Bierut LJ, Edenberg HJ, Foroud T (2009) Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am J Med Genet B Neuropsychiatr Genet 150B(5):736–740 - PubMed - PMC - DOI
    1. Amato L, Minozzi S, Mitrova Z, Parmelli E, Saulle R, Cruciani F, Davoli M (2017) Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy. Epidemiol Prev 41(5–6):279–293 - PubMed
    1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington, VA - DOI